View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
February 27, 2020

Tonix Pharmaceuticals forms alliance to develop Covid-19 vaccine

Tonix Pharmaceuticals has partnered with non-profit Southern Research to develop a vaccine against Covid-19 using the former’s horsepox vaccine platform.


Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates

Free Whitepaper
img

What is the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry?

While wanting to protect the country from being overwhelmed by Omicron, China’s adherence to a Zero-COVID policy is resulting in a significant economic downturn. COVID outbreaks in Shanghai, Beijing and many other Chinese cities will impact 2022’s economic growth as consumers and businesses experience rolling lockdowns, leading to a slowdown in domestic and international supply chains. China’s Zero-COVID policy is having a demonstrable impact on consumer-facing industries. Access GlobalData’s new whitepaper, China in 2022: the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry, to examine the current situation in Shanghai and other cities in China, to better understand the worst-affected industry sectors, foodservice in particular, and to explore potential growth opportunities as China recovers. The white paper covers:
  • Which multinational companies have been affected?
  • What is the effect of lockdowns on foodservice?
  • What is the effect of lockdowns on Chinese ports?
  • Spotlight on Shanghai: what is the situation there?
  • How have Chinese consumers reacted?
  • How might the Chinese government react?
  • What are the potential growth opportunities?
by GlobalData
Enter your details here to receive your free Whitepaper.

Follow the latest updates of the outbreak on our timeline.

Tonix Pharmaceuticals has partnered with non-profit Southern Research to develop a vaccine against Covid-19 using the former’s horsepox vaccine platform.

The partners intend to work on TNX-1800, a live modified horsepox virus vaccine formulated for percutaneous administration.

Tonix Pharmaceuticals is currently developing TNX-801, live horsepox virus vaccine for percutaneous administration, to potentially prevent smallpox and monkeypox.

As part of the latest research alliance, the companies will develop and evaluate TNX-1800 as a potential coronavirus vaccine. The vaccine candidate is said to express a protein from the new coronavirus, SARS-CoV-2.

It is believed that a horsepox virus possesses the potential to act as a vector for vaccines against other infections.

According to previous reports from Tonix, horsepox has efficacy as a potential vaccine with good tolerability in mice and macaques.

The company added that horsepox is similar to vaccinia vaccines, a group of orthopoxviruses used as smallpox vaccines.

Tonix Pharmaceuticals CEO Dr Seth Lederman said: “Although vaccinia vectors are available, different orthopoxvirus strains may behave differently as vectors in part because of their different repertoire of genes that modulate immune responses and host range.

“Potential advantages of horsepox are the strong immunogenicity we observed in macaques and mice with good tolerability. The protein synthesis connected with a replicating live virus vaccine provides direct antigen presentation, which can stimulate cellular immunity in addition to humoral immunity.”

Southern Research will assess one or more Tonix horsepox vector-based vaccine constructs, which express one or more SARS-CoV-2 proteins or protein fragments.

The non-profit research organisation’s senior scientist Scott Goebel has experience with vaccinia and orthopoxvirus vaccines research. Goebel also studied coronaviruses.


See all Coronavirus vaccines and drugs in the pipeline

Related Companies

Free Whitepaper
img

What is the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry?

While wanting to protect the country from being overwhelmed by Omicron, China’s adherence to a Zero-COVID policy is resulting in a significant economic downturn. COVID outbreaks in Shanghai, Beijing and many other Chinese cities will impact 2022’s economic growth as consumers and businesses experience rolling lockdowns, leading to a slowdown in domestic and international supply chains. China’s Zero-COVID policy is having a demonstrable impact on consumer-facing industries. Access GlobalData’s new whitepaper, China in 2022: the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry, to examine the current situation in Shanghai and other cities in China, to better understand the worst-affected industry sectors, foodservice in particular, and to explore potential growth opportunities as China recovers. The white paper covers:
  • Which multinational companies have been affected?
  • What is the effect of lockdowns on foodservice?
  • What is the effect of lockdowns on Chinese ports?
  • Spotlight on Shanghai: what is the situation there?
  • How have Chinese consumers reacted?
  • How might the Chinese government react?
  • What are the potential growth opportunities?
by GlobalData
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology